Final Opportunity to Invest in FemTech III –
Fund Closing Now

Portfolia’s highly acclaimed FemTech Fund III is closing now.


Members in the fund have 10 days to increase commitments.

Next Pitch Call

January 8, 2025 | 9:30 AM PT

Every month, members will have the opportunity to join in on the pitch calls with other members and our lead partners. We always welcome your business questions and consumer expertise, but if you can’t attend, you’ll always be able to listen to the recording on your dashboard when it’s more convenient.

 

Portfolio Companies | In the News

Missed the last pitch call? Catch up here!

FemTech III Portfolio Highlights

Annual Fund Report

2023 FemTech III Fund Performance Updates

The 2023 financial statements are as of and for December 31, 2023. Please note all updates provided are confidential and not for distribution.

The Companies & Leadership Team

The Portfolia FemTech III Fund is led by a world-class team of highly sophisticated and experienced investors who are leaders in their respective fields, as venture capitalists, angel investors, and innovators. They bring an expert skill-set including sourcing, diligence, deal negotiation, executive recruitment, strategy and governance. Click on photos for full bios.

The Companies

Company Logo Gallery
Apollo Neuroscience

Apollo Neuro offers a wearable consumer wellness device intended to help manage stress, challenging life transitions, and to promote a healthy lifestyle.

Attn: Grace

Attn Grace is a sustainable wellness brand designed for women, creating more sustainable solutions for women to combat bladder leakage.

Inherent Biosciences

A molecular diagnostics company at the intersection of epigenetics and AI tackling clinical problems where epigenetics appears to be involved such as infertility.

Maude

Maude is setting new standards for sexual wellness and works closely with factories to create body-safe, accessible essentials for all.

FemDx

FEMDX is a developer of cancer diagnosis devices designed to detect ovarian cancer.

Simple HealthKit

Simple Health Kit provides high-quality, accessible, and affordable diagnostic services for chronic health conditions.

Neuspera

Neuspera develops ultra-miniaturized, implantable medical devices for treating chronic conditions such as Overactive Bladder (OAB).

Hera Biotech

Developer of definitive tissue-based tests designed to diagnose and stage endometriosis.

The Leadership Team

Companies In Diligence

If there are no companies in diligence currently, you can still volunteer and we'll contact you when a new one is being assembled

Featured
Ovala offers a medical device (Revive) designed to temporarily alleviate urine leakage resulting from stress urinary incontinence (SUI) in women. 

Ovala offers a medical device (Revive) designed to temporarily alleviate urine leakage resulting from stress urinary incontinence (SUI) in women. 

b.well’s comprehensive platform unifies data, solutions and services in one place — empowering providers, payers, retail pharmacies, and healthcare technology companies to deliver frictionless, personalized healthcare experiences.

b.well’s comprehensive platform unifies data, solutions and services in one place — empowering providers, payers, retail pharmacies, and healthcare technology companies to deliver frictionless, personalized healthcare experiences.

Aria CV has developed an implantable cardiovascular device designed to treat pulmonary hypertension most commonly developed in women. The device reduces the workload on the heart with the potential to enhance both the survival and quality of life.

Aria CV has developed an implantable cardiovascular device designed to treat pulmonary hypertension most commonly developed in women. The device reduces the workload on the heart with the potential to enhance both the survival and quality of life.

Clear Gene’s tests help eradicate cancer by telling doctors whether they got it all, at a curable stage. The company is starting with breast cancer using advances in data science to analyze gene activity, which promises to save thousands of lives an

Clear Gene’s tests help eradicate cancer by telling doctors whether they got it all, at a curable stage. The company is starting with breast cancer using advances in data science to analyze gene activity, which promises to save thousands of lives and $3 billion in annual healthcare costs.

FEMSelect develops the EnPlace delivery system, a minimally invasive device that treats pelvic organ prolapse (POP). ncer.

FEMSelect develops the EnPlace delivery system, a minimally invasive device that treats pelvic organ prolapse (POP). ncer.

Materna is a medical technology company transforming the standard of care in OBGYN with core technologies addressing unmet needs developing products (Milli and Materna Prep) to improve women's pelvic and sexual health. 

Materna is a medical technology company transforming the standard of care in OBGYN with core technologies addressing unmet needs developing products (Milli and Materna Prep) to improve women's pelvic and sexual health. 

Refer A Company

The FemTech III fund will invest in 8-12 companies, from Seed to pre-IPO. We consider companies with solutions in the market, and we invest in both female- and male-led teams with a preference for gender-balanced executive teams. We only invest in companies with a U.S.-based C-Corp. Please submit the company information below or email companies@portfolia.com with questions.

Interested in other funds?

Request a guest pass for one of their pitch calls

 

Additional questions?

Reach out to our team